EuroPCR 2018 | TRANSIENT trial: What is the best timing for TRANSIENT STEMI revascularization?

The objective of this study was to determine the best time to revascularize a patient who is undergoing an acute coronary syndrome (ACS) with transient ST segment elevation.

This population hovers around 15% of STEMI patients. The question is whether to reduce infarction area (or potential reinfarction) with an immediate intervention, or to delay intervention to allow plaque stabling and reduce thrombus load. The current guidelines do not include this scenario, which is what makes this study so interesting from a physiopathological point of view.

 

The study included 142 patients arriving with ST elevation MI and chest pain whose symptoms resolved upon emergency handling: ST normalized and chest pain disappeared. Patients were then randomized to angiography and immediate revascularization vs. delayed revascularization. Primary end point was infarction size by MRI at 4 days, and clinical end point was at 30 days.


Read also: EuroPCR 2018 | RADIANCE-HTN SOLO: Renal Denervation Guided Through Intravascular Ultrasound.


There were no differences in primary end point between both branches and they both had favorable short term clinical results. Only 5.6% of patients randomized to the delayed strategy needed to be transferred to the cath lab for an emergency procedure due to changes in EKG or symptoms of repeat STEMI.  

 

Original title: What is the optimal timing of revascularisation in transient STEMI? The TRANSIENT trial.

Presenter: Lemkes Jorrit.

 

TRANSIENT-TRIAL


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....